Adjuvantation helps to optimise COVID-19 vaccine candidate
- PMID: 33705726
- PMCID: PMC8221731
- DOI: 10.1016/S1473-3099(21)00094-3
Adjuvantation helps to optimise COVID-19 vaccine candidate
Comment on
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21. Lancet Infect Dis. 2021. PMID: 33485468 Free PMC article. Clinical Trial.
References
-
- WHO . World Health Organization; Geneva: Feb 2021. COVID-19 weekly epidemiological update – 2 February 2021.
-
- Ella R, Reddy S, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00070-0. published online March 8. - DOI - PMC - PubMed
-
- Sinovac Biotech Sinovac announces phase III results of its COVID-19 vaccine. 2021. http://www.sinovac.com/?optionid=754&auto_id=922
-
- Lee G, Mak E. China's CNBG/Sinopharm COVID-19 vaccine is 79% effective. 2021. https://www.bioworld.com/articles/501906-chinas-cnbgsinopharm-covid-19-v...
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical